271 related articles for article (PubMed ID: 27322423)
21. A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells.
Ischenko I; Petrenko O; Hayman MJ
Oncotarget; 2015 Jun; 6(18):15814-27. PubMed ID: 26158412
[TBL] [Abstract][Full Text] [Related]
22. Role of GRP78 inhibiting artesunate-induced ferroptosis in
Wang K; Zhang Z; Wang M; Cao X; Qi J; Wang D; Gong A; Zhu H
Drug Des Devel Ther; 2019; 13():2135-2144. PubMed ID: 31456633
[No Abstract] [Full Text] [Related]
23. Hypoxia-induced lncRNA-NUTF2P3-001 contributes to tumorigenesis of pancreatic cancer by derepressing the miR-3923/KRAS pathway.
Li X; Deng SJ; Zhu S; Jin Y; Cui SP; Chen JY; Xiang C; Li QY; He C; Zhao SF; Chen HY; Niu Y; Liu Y; Deng SC; Wang CY; Zhao G
Oncotarget; 2016 Feb; 7(5):6000-14. PubMed ID: 26755660
[TBL] [Abstract][Full Text] [Related]
24. Discovery of KRB-456, a KRAS G12D Switch-I/II Allosteric Pocket Binder That Inhibits the Growth of Pancreatic Cancer Patient-derived Tumors.
Kazi A; Ranjan A; Kumar M V V; Agianian B; Garcia Chavez M; Vudatha V; Wang R; Vangipurapu R; Chen L; Kennedy P; Subramanian K; Quirke JCK; Beato F; Underwood PW; Fleming JB; Trevino J; Hergenrother PJ; Gavathiotis E; Sebti SM
Cancer Res Commun; 2023 Dec; 3(12):2623-2639. PubMed ID: 38051103
[TBL] [Abstract][Full Text] [Related]
25. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
[TBL] [Abstract][Full Text] [Related]
26. RAS-RAF-miR-296-3p signaling axis increases Rad18 expression to augment radioresistance in pancreatic and thyroid cancers.
Wolfe AR; Feng H; Zuniga O; Rodrigues H; Eldridge DE; Yang L; Shen C; Williams TM
Cancer Lett; 2024 Jun; 591():216873. PubMed ID: 38604313
[TBL] [Abstract][Full Text] [Related]
27. A CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment.
Zhao X; Liu L; Lang J; Cheng K; Wang Y; Li X; Shi J; Wang Y; Nie G
Cancer Lett; 2018 Sep; 431():171-181. PubMed ID: 29870774
[TBL] [Abstract][Full Text] [Related]
28. Critical role of oncogenic KRAS in pancreatic cancer (Review).
Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
[TBL] [Abstract][Full Text] [Related]
29. Chimeric ubiquitin ligases inhibit non-small cell lung cancer via negative modulation of EGFR signaling.
Zhong D; Ru Y; Wang Q; Zhang J; Zhang J; Wei J; Wu J; Yao L; Li X; Li X
Cancer Lett; 2015 Apr; 359(1):57-64. PubMed ID: 25573345
[TBL] [Abstract][Full Text] [Related]
30. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
31. EGFR High Expression, but not KRAS Status, Predicts Sensitivity of Pancreatic Cancer Cells to Nimotuzumab Treatment In Vivo.
Zhou C; Zhu L; Ji J; Ding F; Wang C; Cai Q; Yu Y; Zhu Z; Zhang J
Curr Cancer Drug Targets; 2017; 17(1):89-97. PubMed ID: 27739365
[TBL] [Abstract][Full Text] [Related]
32. GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors.
Kazi A; Xiang S; Yang H; Delitto D; Trevino J; Jiang RHY; Ayaz M; Lawrence HR; Kennedy P; Sebti SM
Nat Commun; 2018 Dec; 9(1):5154. PubMed ID: 30514931
[TBL] [Abstract][Full Text] [Related]
33. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
[TBL] [Abstract][Full Text] [Related]
34. Dynamic Regulation of Expression of KRAS and Its Effectors Determines the Ability to Initiate Tumorigenesis in Pancreatic Acinar Cells.
Assi M; Achouri Y; Loriot A; Dauguet N; Dahou H; Baldan J; Libert M; Fain JS; Guerra C; Bouwens L; Barbacid M; Lemaigre FP; Jacquemin P
Cancer Res; 2021 May; 81(10):2679-2689. PubMed ID: 33602788
[TBL] [Abstract][Full Text] [Related]
35. miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer.
Yu S; Lu Z; Liu C; Meng Y; Ma Y; Zhao W; Liu J; Yu J; Chen J
Cancer Res; 2010 Jul; 70(14):6015-25. PubMed ID: 20610624
[TBL] [Abstract][Full Text] [Related]
36. U1 Adaptors Suppress the
Tsang AT; Dudgeon C; Yi L; Yu X; Goraczniak R; Donohue K; Kogan S; Brenneman MA; Ho ES; Gunderson SI; Carpizo DR
Mol Cancer Ther; 2017 Aug; 16(8):1445-1455. PubMed ID: 28377488
[TBL] [Abstract][Full Text] [Related]
37. Dependence on the Pyrimidine Biosynthetic Enzyme DHODH Is a Synthetic Lethal Vulnerability in Mutant KRAS-Driven Cancers.
Koundinya M; Sudhalter J; Courjaud A; Lionne B; Touyer G; Bonnet L; Menguy I; Schreiber I; Perrault C; Vougier S; Benhamou B; Zhang B; He T; Gao Q; Gee P; Simard D; Castaldi MP; Tomlinson R; Reiling S; Barrague M; Newcombe R; Cao H; Wang Y; Sun F; Murtie J; Munson M; Yang E; Harper D; Bouaboula M; Pollard J; Grepin C; Garcia-Echeverria C; Cheng H; Adrian F; Winter C; Licht S; Cornella-Taracido I; Arrebola R; Morris A
Cell Chem Biol; 2018 Jun; 25(6):705-717.e11. PubMed ID: 29628435
[TBL] [Abstract][Full Text] [Related]
38. LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.
Zhou J; Zheng B; Ji J; Shen F; Min H; Liu B; Wu J; Zhang S
Tumour Biol; 2015 May; 36(5):3301-8. PubMed ID: 25524577
[TBL] [Abstract][Full Text] [Related]
39. An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors.
Indarte M; Puentes R; Maruggi M; Ihle NT; Grandjean G; Scott M; Ahmed Z; Meuillet EJ; Zang S; Lemos R; Du-Cuny L; Layng FIAL; Correa RG; Bankston LA; Liddington RC; Kirkpatrick L; Powis G
Cancer Res; 2019 Jun; 79(12):3100-3111. PubMed ID: 31040156
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of Chronic Pancreatitis and Murine Pancreatic Intraepithelial Neoplasia by a Dual Inhibitor of c-RAF and Soluble Epoxide Hydrolase in LSL-KrasG¹²D/Pdx-1-Cre Mice.
Liao J; Hwang SH; Li H; Liu JY; Hammock BD; Yang GY
Anticancer Res; 2016 Jan; 36(1):27-37. PubMed ID: 26722025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]